Literature DB >> 11166061

Acute neuroactive steroid withdrawal in withdrawal seizure-prone and withdrawal seizure-resistant mice.

M T Reilly1, J C Crabbe, N R Rustay, D A Finn.   

Abstract

Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one) is an endogenously derived metabolite of progesterone, and a potent positive modulator of gamma-aminobutyric acid(A) (GABA(A)) receptors. A withdrawal syndrome, characterized by central nervous system (CNS) hyperexcitability, has been demonstrated following abrupt discontinuation of high progesterone levels in rats, which was due in part to altered levels of allopregnanolone. The purpose of the present study was to determine if a single administration of pregnanolone or allopregnanolone could produce an acute withdrawal response in mice selected for susceptibility (Withdrawal Seizure-Prone, WSP) or resistance (Withdrawal Seizure-Resistant, WSR) to ethanol withdrawal convulsions. WSP mice administered 75 mg/kg pregnanolone showed a significant increase in handling-induced convulsion (HIC) scores over a 25-h testing period. In contrast, HIC scores in WSR mice were negligible after acute administration of 25, 50, 75, or 100 mg/kg pregnanolone. WSP mice also showed a similar increase in HIC after withdrawal from 75 mg/kg allopregnanolone. This effect was evident at both the 10-h and 25-h overall withdrawal severity assessment. These results demonstrate that neuroactive steroids can elicit an acute withdrawal response similar to that of other positive modulators of GABA(A) receptors in WSP mice, supporting the notion that a common set of genes underlie acute and chronic withdrawal severity from multiple agents with depressant effects on the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11166061     DOI: 10.1016/s0091-3057(00)00416-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

Review 1.  Pharmacogenetic studies of alcohol self-administration and withdrawal.

Authors:  John C Crabbe; Tamara J Phillips
Journal:  Psychopharmacology (Berl)       Date:  2003-10-09       Impact factor: 4.530

2.  Ethanol tolerance and withdrawal severity in high drinking in the dark selectively bred mice.

Authors:  John C Crabbe; Alexandre M Colville; Lauren C Kruse; Andy J Cameron; Stephanie E Spence; Jason P Schlumbohm; Lawrence C Huang; Pamela Metten
Journal:  Alcohol Clin Exp Res       Date:  2012-02-06       Impact factor: 3.455

3.  Sex differences in anxiety, sensorimotor gating and expression of the alpha4 subunit of the GABAA receptor in the amygdala after progesterone withdrawal.

Authors:  M Gulinello; R Orman; S S Smith
Journal:  Eur J Neurosci       Date:  2003-02       Impact factor: 3.386

4.  Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal profile in adrenalectomy/gonadectomy mice.

Authors:  K R Kaufman; M A Tanchuck; M N Strong; D A Finn
Journal:  Neuroscience       Date:  2010-01-06       Impact factor: 3.590

Review 5.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

6.  Chromosomal loci influencing chronic alcohol withdrawal severity.

Authors:  Susan E Bergeson; R Kyle Warren; John C Crabbe; Pamela Metten; V Gene Erwin; John K Belknap
Journal:  Mamm Genome       Date:  2003-07       Impact factor: 2.957

7.  Progesterone withdrawal increases the alpha4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology - a comparison with female rats.

Authors:  M Gulinello; Q H Gong; S S Smith
Journal:  Neuropharmacology       Date:  2002-09       Impact factor: 5.250

8.  Seizing an opportunity: broader definitions of epilepsy may lead to better treatments.

Authors:  Helen E Scharfman
Journal:  Cerebrum       Date:  2010-09-22

Review 9.  Catamenial Epilepsy: Discovery of an Extrasynaptic Molecular Mechanism for Targeted Therapy.

Authors:  Doodipala Samba Reddy
Journal:  Front Cell Neurosci       Date:  2016-04-22       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.